California State Teachers Retirement System Acquires 2,959 Shares of Assembly Biosciences (ASMB)

California State Teachers Retirement System raised its holdings in Assembly Biosciences (NASDAQ:ASMB) by 13.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,398 shares of the biopharmaceutical company’s stock after acquiring an additional 2,959 shares during the period. California State Teachers Retirement System owned approximately 0.13% of Assembly Biosciences worth $1,149,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ASMB. The Manufacturers Life Insurance Company increased its holdings in shares of Assembly Biosciences by 15,448.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,195 shares of the biopharmaceutical company’s stock worth $232,000 after buying an additional 11,123 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Assembly Biosciences by 10.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 47,317 shares of the biopharmaceutical company’s stock worth $1,653,000 after purchasing an additional 4,330 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Assembly Biosciences by 6.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock worth $5,944,000 after purchasing an additional 11,412 shares during the period. Wells Fargo & Company MN boosted its position in shares of Assembly Biosciences by 148.5% during the 3rd quarter. Wells Fargo & Company MN now owns 25,600 shares of the biopharmaceutical company’s stock worth $894,000 after purchasing an additional 15,300 shares during the period. Finally, OxFORD Asset Management LLP boosted its position in shares of Assembly Biosciences by 26.6% during the 3rd quarter. OxFORD Asset Management LLP now owns 66,227 shares of the biopharmaceutical company’s stock worth $2,220,000 after purchasing an additional 13,925 shares during the period. Institutional investors own 76.81% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of ASMB stock opened at $44.61 on Friday. Assembly Biosciences has a 52 week low of $18.60 and a 52 week high of $67.36. The company has a market capitalization of $938.65, a price-to-earnings ratio of -17.36 and a beta of 0.74.

In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $46.86, for a total value of $46,860.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 3,000 shares of company stock valued at $152,550 in the last three months. 19.60% of the stock is currently owned by corporate insiders.

A number of equities analysts recently weighed in on the stock. BidaskClub cut shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 14th. Jefferies Group increased their price objective on shares of Assembly Biosciences to $75.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. ValuEngine raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 3rd. Finally, B. Riley assumed coverage on shares of Assembly Biosciences in a research report on Friday, January 5th. They set a “neutral” rating and a $35.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $54.25.

TRADEMARK VIOLATION WARNING: “California State Teachers Retirement System Acquires 2,959 Shares of Assembly Biosciences (ASMB)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/california-state-teachers-retirement-system-acquires-2959-shares-of-assembly-biosciences-asmb.html.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply